Yuhan's Stake in ImmuneOncia Drops from 67.37% to 57.23% After Rights Offering... Dilution Risk and Price Impact in Focus
Yuhan (the reporter) participated in ImmuneOncia's rights offering, acquiring 2,741,669 new shares (approximately KRW 13.3 billion) at KRW 4,860 each, increasing its total holdings from 52,523,598 to 52,870,177 shares; however, as the total outstanding shares rose from 74,363,829 to 91,194,029, its stake dropped by 10.14 percentage points from 67.37% to 57.23%
The entire acquisition cost was funded by Yuhan's own capital (approx. KRW 13.3 billion), including oversubscription of 345,503 shares, indicating the reporter's active commitment
The offering price of KRW 4,860 is approximately 21.6% below the current market price of KRW 6,200, creating dilution and per-share value erosion for existing shareholders
Although the reporter states no intent to change control, the significant reduction in the largest shareholder's stake may raise investor concerns about future management stability
No share buyback, cancellation, or dividend information is included in this report, indicating no change in shareholder return policy
[AI Comprehensive Analysis]While Yuhan's absolute share count increased, the dilution caused by the rise in total outstanding shares is likely to negatively impact the stock price in the short term. However, if the raised funds are used for R&D or facility investment at ImmuneOncia, it could enhance long-term enterprise value, so monitoring the use of proceeds is essential.